Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Fridman

Showing results (61-70 of 98) with videos related to

Pageof 10
Sort By:
European Journal of Pediatrics|November 14, 2013
Reply to L. Reale et al. "More and better should be done to guarantee evidence-based management of ADHD in children across Europe"Paul Hodgkins, Juliana Setyawan, Debanjali Mitra, et al.
Journal of Managed Care Pharmacy : JMCP|November 14, 2003
Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapyShane D Scott, Elizabeth A Chrischilles, Brian K Link, et al.
American Journal of Obstetrics and Gynecology|March 18, 2014
Monitoring childbirth morbidity using hospital discharge data: further development and application of a composite measureLisa M Korst, Moshe Fridman, Michael C Lu, et al.
Journal of Managed Care & Specialty Pharmacy|February 8, 2019
Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic ControlSwapna Karkare, Moshe Fridman, Tam Dang-Tan, et al.
Cancer|September 24, 2005
Dose-dense vinorelbine and docetaxel with Filgrastim support in patients with advanced nonsmall cell lung carcinomaRay D Page, Frederick P Smith, George F Geils, et al.
Leukemia & Lymphoma|June 7, 2006
Severe neutropenia in CHOP occurs most frequently in cycle 1: a predictive modelArthur P Rabinowitz, Neil J Weiner, Bruce S Tronic, et al.
Journal of the Endocrine Society|March 13, 2025
Adult Growth Hormone Deficiency (AGHD) and Outcomes (NordiNet and ANSWER)John D Carmichael, Atil Y Kargi, Laura Dichtel, et al.
American Journal of Obstetrics and Gynecology|April 9, 2008
Vaginal birth after cesarean: clinical risk factors associated with adverse outcomeKimberly D Gregory, Lisa M Korst, Moshe Fridman, et al.
Policy, Politics & Nursing Practice|March 14, 2008
Mandated nurse staffing ratios in California: a comparison of staffing and nursing-sensitive outcomes pre- and postregulationLinda Burnes Bolton, Carolyn E Aydin, Nancy Donaldson, et al.
Clinical Lymphoma & Myeloma|June 15, 2007
Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patientsDelvyn C Case, Christopher E Desch, Leonard A Kalman, et al.
Pageof 10

Showing results (61-70 of 98) with videos related to

Sort By:
Pageof 10
European Journal of Pediatrics|November 14, 2013
Reply to L. Reale et al. "More and better should be done to guarantee evidence-based management of ADHD in children across Europe"Paul Hodgkins, Juliana Setyawan, Debanjali Mitra, et al.
Journal of Managed Care Pharmacy : JMCP|November 14, 2003
Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin's lymphoma treated with chemotherapyShane D Scott, Elizabeth A Chrischilles, Brian K Link, et al.
American Journal of Obstetrics and Gynecology|March 18, 2014
Monitoring childbirth morbidity using hospital discharge data: further development and application of a composite measureLisa M Korst, Moshe Fridman, Michael C Lu, et al.
Journal of Managed Care & Specialty Pharmacy|February 8, 2019
Effect of Weight Change on Economic Outcomes Among Persons with Type 2 Diabetes Mellitus in the United States: Beyond Glycemic ControlSwapna Karkare, Moshe Fridman, Tam Dang-Tan, et al.
Cancer|September 24, 2005
Dose-dense vinorelbine and docetaxel with Filgrastim support in patients with advanced nonsmall cell lung carcinomaRay D Page, Frederick P Smith, George F Geils, et al.
Leukemia & Lymphoma|June 7, 2006
Severe neutropenia in CHOP occurs most frequently in cycle 1: a predictive modelArthur P Rabinowitz, Neil J Weiner, Bruce S Tronic, et al.
Journal of the Endocrine Society|March 13, 2025
Adult Growth Hormone Deficiency (AGHD) and Outcomes (NordiNet and ANSWER)John D Carmichael, Atil Y Kargi, Laura Dichtel, et al.
American Journal of Obstetrics and Gynecology|April 9, 2008
Vaginal birth after cesarean: clinical risk factors associated with adverse outcomeKimberly D Gregory, Lisa M Korst, Moshe Fridman, et al.
Policy, Politics & Nursing Practice|March 14, 2008
Mandated nurse staffing ratios in California: a comparison of staffing and nursing-sensitive outcomes pre- and postregulationLinda Burnes Bolton, Carolyn E Aydin, Nancy Donaldson, et al.
Clinical Lymphoma & Myeloma|June 15, 2007
Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patientsDelvyn C Case, Christopher E Desch, Leonard A Kalman, et al.
Pageof 10